Keeping Track: Approval Of First Intranasal Naloxone Copycat Highlights Otherwise Generic Week

 
• By Michael Cipriano and Brenda Sandburg
Keeping Track Feature image
Viela Bio's inebilizumab for NMOSD and Genfit's elafibranor for PBC win breakthrough designations; Novartis uses priority review voucher for wet AMD treatment brolucizumab.

More from Product Reviews

More from Pink Sheet